1. Plasma IL-1 receptor antagonist levels correlate with the development of non-alcoholic steatohepatitis
- Author
-
Patrick J. van Gorp, Tom Houben, Marten H. Hofker, Satish C. Kalhan, Mike L. J. Jeurissen, Tim Hendrikx, Ronit Shiri-Sverdlov, Jussi Pihlajamäki, Ger H. Koek, Sofie M. A. Walenbergh, Patrick J. Lindsey, Center for Liver, Digestive and Metabolic Diseases (CLDM), Vascular Ageing Programme (VAP), Moleculaire Genetica, Moleculaire Celbiologie, Interne Geneeskunde, RS: NUTRIM - R2 - Gut-liver homeostasis, RS: GROW - Developmental Biology, and RS: GROW - R4 - Reproductive and Perinatal Medicine
- Subjects
Adult ,Male ,medicine.medical_specialty ,medicine.drug_class ,diagnosis ,Clinical Biochemistry ,Inflammation ,Disease ,digestive system ,Liver disease ,Non-alcoholic Fatty Liver Disease ,Internal medicine ,NAFLD ,Drug Discovery ,medicine ,Humans ,FATTY LIVER-DISEASE ,hepatic inflammation ,business.industry ,Biochemistry (medical) ,Case-control study ,NASH ,nutritional and metabolic diseases ,Middle Aged ,medicine.disease ,Receptor antagonist ,CYTOKERATIN-18 ,digestive system diseases ,Interleukin 1 Receptor Antagonist Protein ,MICE ,Endocrinology ,IL-1Ra ,Liver ,ROC Curve ,Case-Control Studies ,OBESITY ,Cohort ,Female ,Steatosis ,medicine.symptom ,Steatohepatitis ,business - Abstract
Aim: Nonalcoholic steatohepatitis (NASH) is a liver disease characterized by lipid accumulation and inflammation. Here, we aimed to evaluate plasma IL-1Ra as a marker for NASH and to determine whether diagnosis of NASH can be further improved by adding IL-1Ra measurements. Materials & methods: Therefore, plasma concentrations of IL-1Ra were measured from 146 subjects of a biopsy-proven NASH cohort with matched controls. Results: NASH patients had higher levels of plasma IL-1Ra compared with patients with steatosis or healthy controls. Conclusion: Our data confirm that IL-1Ra can be a useful tool in the diagnosis of hepatic inflammation and suggest that measuring plasma IL-1Ra levels in addition to ALT will improve the diagnosis for NASH at all stages of the disease.
- Published
- 2015
- Full Text
- View/download PDF